Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 6/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7537746 | 0.88 | HDAC4 (0.54) | HDAC4RORCTSHRTP53MAPT | |
| SCHEMBL5164306 | 0.87 | HDAC4 (0.48) | HDAC4RORCTP53MAPTHIF1A | |
| SCHEMBL5166405 | 0.86 | HDAC4 (0.43) | HDAC4RORCTSHRTP53MAPT | |
| SCHEMBL7537578 | 0.82 | CYP3A4 (0.45) | HDAC4RORCTP53MEN1KMT2A | |
| SCHEMBL1573840 | 0.81 | HDAC4 (0.48) | HDAC4RORCTP53MAPTHIF1A | |
| Laquinimod SCHEMBL39440 | 0.81 | TP53 (0.50) | HDAC4RORCTSHRTP53MEN1 | |
| Laquinimod SCHEMBL29438575 | 0.81 | TP53 (0.50) | HDAC4RORCTSHRTP53MEN1 | |
| SCHEMBL7538308 | 0.80 | HDAC4 (0.54) | HDAC4RORCTSHRTP53MAPT | |
| SCHEMBL23531675 | 0.80 | HDAC4 (0.43) | HDAC4RORCTP53MEN1KMT2A | |
| SCHEMBL7538318 | 0.80 | HDAC4 (0.43) | HDAC4RORCTP53MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020173520-A1 | Quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173520-A1 | Quinoline derivatives | CYP4F3, IRF3, CXCR3 | HDAC4 2957/4885RORC 603/4885TSHR 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.